Exelixis | Srodki Pieniężne I Ekwiwalent



Cash And Equivalent Zmiana Data
Acadia Pharmaceuticals USD 755.99M 190.66M 2024-12
Agios Pharmaceuticals USD 76.25M 177.48M 2024-12
Amgen USD 11.97B 2.96B 2024-12
AstraZeneca USD 5.23B 258M 2025-03
Bayer EUR 6.19B 1.57B 2024-12
BioMarin Pharmaceutical USD 613.22M 324.54M 2024-12
Bristol-Myers Squibb USD 10.88B 529M 2025-03
Cytokinetics USD 94.86M 47.97M 2024-12
Eisai JPY 291.26B 22.65B 2024-12
Eli Lilly USD 3.27B 100.6M 2024-12
Exelixis USD 217.37M 40.97M 2025-01
Genmab DKK 9.86B 3.52B 2024-12
Glaxosmithkline GBP 3.87B 678M 2024-12
Incyte USD 2.41B 720.83M 2025-03
Ionis Pharmaceuticals USD 242.08M 92.53M 2024-12
MacroGenics USD 182.84M 3.22M 2024-12
Merck USD 13.24B 1.35B 2024-12
Moderna USD 1.93B 283M 2024-12
Neurocrine Biosciences USD 233M 116.1M 2024-12
Novartis USD 8.87B 4.74B 2024-12
Pfizer USD 1.04B 49M 2024-12
Sanofi 7.44B 646M 2024-12
Takeda JPY 494.13B 364.89B 2024-12
Ultragenyx Pharmaceutical USD 173.73M 23.11M 2024-12
Xencor USD 40.88M 11.84M 2024-12



Exelixis Srodki Pieniężne I Ekwiwalent - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - Apr 2025.